Haemonetics Posts Investor Update

Wednesday, September 10, 2008 General News J E 4
BRAINTREE, Mass., Sept. 10 HaemoneticsCorporation (NYSE: HAE) announced today that the Company will be hostinginvestor meetings during September. As part of these meetings, Haemonetics'management will review previously discussed guidance which is unchanged fromthe Company's August 1, 2008 press release.

The content of the meeting presentations is available on the Company'swebsite at

Haemonetics (NYSE: HAE) is a global healthcare company dedicated toproviding innovative blood management solutions for our customers. Together,our devices and consumables, IT products, and consulting services deliver asuite of business solutions to help our customers improve clinical outcomesand reduce the cost of healthcare for blood collectors, hospitals, andpatients around the world. Our technologies address important medicalmarkets: blood and plasma component collection, the surgical suite, andhospital transfusion services. To learn more about Haemonetics, visit our website at

This release contains forward-looking statements that involve risks anduncertainties, including technological advances in the medical field andstandards for transfusion medicine and our ability to successfully implementproducts that incorporate such advances and standards, product demand, marketacceptance, regulatory uncertainties, the effect of economic and politicalconditions, the impact of competitive products and pricing, blood productreimbursement policies and practices, foreign currency exchange rates, changesin customers' ordering patterns, the effect of industry consolidation as seenin the plasma market, the effect of communicable diseases and the effect ofuncertainties in markets outside the U.S. (including Europe and Asia) in whichwe operate and other risks detailed in the Company's filings with theSecurities and Exchange Commission. The foregoing list should not beconstrued as exhaustive. The forward-looking statements are based onestimates and assumptions made by management of the Company and are believedto be reasonable, though are inherently uncertain and difficult to predict.Actual results and experience could differ materially from the forward-lookingstatements.Contact: Julie Fallon Tel. (781) 356-9517 Alt. Tel. (617) 320-2401

SOURCE Haemonetics Corporation


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Stonyfield Puts a Lid on It for Stand Up to Cancer...
Halozyme Therapeutics to Present at Upcoming Inves...